ATTAINMENT: A phase Ib trial of MDX-124, a first-in-class annexin-A1 targeting antibody, alone and in combination with anti-cancer treatments, in patients with advanced solid tumors.
Daniel H. Palmer(University of Liverpool), Sarah P. Blagden(Churchill Hospital), Silviya Balabanova, Stefan N. Symeonides(Edinburgh Cancer Research), Ruth Knight, Jemma Proudfoot-Jones(University of Liverpool), Clare Upton, Fiona C. Dempsey, C B Wood, Colin Tennant, Sohail Rooman Javed(MRC Clinical Trials Unit at UCL), Aglaia Skolariki(MRC Clinical Trials Unit at UCL), Samantha S.P. Low(Edinburgh Cancer Research), Scott Crichton
Cited by 4
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
|JNCI Journal of the National Cancer Institute|2013|333